Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc. Design Therapeutics, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. Longboard Pharmaceuticals, Inc. closed its initial public offering of 5 million shares of its common stock at...
You must be a Standard 1 Year member to access this content.
